Bone Biologics Corp, headquartered in Burlington, Massachusetts with 2 employees, focuses on bone regeneration in spinal fusion using NELL-1, a recombinant human protein. The company, which went public in 2015, develops technologies for various bone-related medical procedures.
Bone Biologics Corp (BBLG) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Bone Biologics Corp's actual EPS was -$0.67, beating the estimate of -$1.42 per share, resulting in a 52.74% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
